The Antibiotic Novobiocin Binds and Activates the ATPase That Powers Lipopolysaccharide Transport.
Ontology highlight
ABSTRACT: Novobiocin is an orally active antibiotic that inhibits DNA gyrase by binding the ATP-binding site in the ATPase subunit. Although effective against Gram-positive pathogens, novobiocin has limited activity against Gram-negative organisms due to the presence of the lipopolysaccharide-containing outer membrane, which acts as a permeability barrier. Using a novobiocin-sensitive Escherichia coli strain with a leaky outer membrane, we identified a mutant with increased resistance to novobiocin. Unexpectedly, the mutation that increases novobiocin resistance was not found to alter gyrase, but the ATPase that powers lipopolysaccharide (LPS) transport. Co-crystal structures, biochemical, and genetic evidence show novobiocin directly binds this ATPase. Novobiocin does not bind the ATP binding site
SUBMITTER: May JM
PROVIDER: S-EPMC5735422 | biostudies-literature | 2017 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA